Skip to main content
Back
FLMNF logo

Fielmann AG

Data quality: 100%
Oversold
FLMNF
OTC Healthcare Medical - Instruments & Supplies
$52.85
$0.00 (0.00%)
Mkt Cap: 4.44B
Also listed as FLMNY OTC
Day Range
$52.85 $52.90
52-Week Range
$42.54 $64.00
Volume
200
50D / 200D Avg
$57.63 / $60.50
Prev Close
$52.85

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E 29.2 0.3
P/B 4.9 2.9
ROE % 18.0 3.7
Net Margin % 6.7 3.8
Rev Growth 5Y % 12.2 10.0
D/E 1.0 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2029 $3.50
$3.41 – $3.57
 2.9 B 6
FY2028 $3.34
$3.26 – $3.41
 2.9 B 7
FY2027 $3.00
$2.93 – $3.07
 2.7 B 6

Key Takeaways

Revenue grew 12.19% annually over 5 years — strong growth
Earnings grew 21.90% over the past year
ROE of 17.99% — decent returns on equity
Generating 327.41M in free cash flow
Cash machine — converts 215.25% of earnings into free cash flow
Capital efficient — spends only 3.65% of revenue on capex

Growth

Revenue Growth (5Y)
12.19%
Revenue (1Y)14.98%
Earnings (1Y)21.90%
FCF Growth (3Y)33.87%

Quality

Return on Equity
17.99%
ROIC14.45%
Net Margin6.72%
Op. Margin15.09%

Safety

Debt / Equity
0.97
Current Ratio0.64
Interest Coverage8.16

Valuation

P/E Ratio
29.18
P/B Ratio4.94
EV/EBITDA15.27
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 14.98% Revenue Growth (3Y) 13.44%
Earnings Growth (1Y) 21.90% Earnings Growth (3Y) 21.14%
Revenue Growth (5Y) 12.19% Earnings Growth (5Y) 6.92%
Profitability
Revenue (TTM) 2.26B Net Income (TTM) 152.11M
ROE 17.99% ROA 6.42%
Gross Margin 80.02% Operating Margin 15.09%
Net Margin 6.72% Free Cash Flow (TTM) 327.41M
ROIC 14.45% FCF Growth (3Y) 33.87%
Safety
Debt / Equity 0.97 Current Ratio 0.64
Interest Coverage 8.16 Dividend Yield 0.02%
Valuation
P/E Ratio 29.18 P/B Ratio 4.94
P/S Ratio 1.96 PEG Ratio 1.06
EV/EBITDA 15.27 Dividend Yield 0.02%
Market Cap 4.44B Enterprise Value 5.22B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 2.26B 1.97B 1.76B 1.68B 1.43B
Net Income 152.11M 124.79M 103.66M 136.86M 116.41M
EPS (Diluted) 1.81 1.49 1.23 1.63 1.39
Gross Profit 1.81B 1.57B 1.38B 1.34B 1.15B
Operating Income 341.68M 648.84M 575.63M 583.61M 179.23M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 2.37B 2.02B 1.77B 1.74B 1.67B
Total Liabilities 1.46B 1.06B 913.48M 863.09M 832.86M
Shareholders' Equity 899.13M 792.03M 804.22M 819.83M 779.20M
Total Debt 873.85M 592.15M 505.66M 458.26M 425.72M
Cash & Equivalents 94.29M 58.93M 51.25M 174.89M 103.72M
Current Assets 545.62M 510.40M 489.95M 538.32M 518.18M
Current Liabilities 846.71M 529.51M 391.79M 366.29M 356.30M

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#439 of 1052
48
Custom Balanced Risk
#142 of 151
27

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Balanced Risk
Mar 24, 2026